JNJ-67856633
98%
- Product Code: 201366
CAS:
2230273-76-2
| Molecular Weight: | 467.32 g./mol | Molecular Formula: | C₂₀H₁₁F₆N₅O₂ |
|---|---|---|---|
| EC Number: | MDL Number: | ||
| Melting Point: | Boiling Point: | ||
| Density: | Storage Condition: | -20°C |
Product Description:
Used in clinical research for the treatment of advanced solid tumors, particularly in patients with NTRK gene fusions. It is an investigational TRK inhibitor designed to target and block the activity of TRKA, TRKB, and TRKC proteins, which are involved in tumor growth and survival. Shows activity against both primary and resistance mutations in NTRK genes, making it a potential option for patients who have progressed on prior TRK inhibitors. Currently being evaluated in phase 1 and 2 trials to assess safety, dosing, and efficacy in various cancer types.
Sizes / Availability / Pricing:
| Size | Availability | Price | Quantity |
|---|---|---|---|
| 5mg | 10-20 days | £233.48 |
+
-
|
JNJ-67856633
Used in clinical research for the treatment of advanced solid tumors, particularly in patients with NTRK gene fusions. It is an investigational TRK inhibitor designed to target and block the activity of TRKA, TRKB, and TRKC proteins, which are involved in tumor growth and survival. Shows activity against both primary and resistance mutations in NTRK genes, making it a potential option for patients who have progressed on prior TRK inhibitors. Currently being evaluated in phase 1 and 2 trials to assess safety, dosing, and efficacy in various cancer types.
| Mechanism | - |
| Appearance | - |
| Longevity | - |
| Strength | - |
| Storage | - |
| Shelf Life | - |
| Allergen(s) | - |
| Dosage (Range) | - |
| Recommended Dosage | - |
| Dosage (Per Day) | - |
| Recommended Dosage (Per Day) | - |
| Mix Method | - |
| Heat Resistance | - |
| Stable in pH range | - |
| Solubility | - |
| Product Types | - |
| INCI | - |
Purchase History for
Loading purchase history...
Cart
No products
Subtotal:
£0.00
£0.00
Total :